Direct Answer
Semax is a synthetic ACTH(4-10) analog heptapeptide studied mainly in Russian research for neuroprotective and nootropic effects.
Summary Table
Evidence Level
Low
AI Summary
Semax is a synthetic heptapeptide analog of ACTH(4-10), developed in Russia and studied primarily by Russian research groups for neuroprotective and nootropic activity. The evidence base is preclinical to low: animal studies describe effects on neurotrophin gene expression, brain monoamine systems, and outcomes in cerebral-ischemia models, and it is reported in Russian clinical use for stroke and cognition. Independent, large controlled international trials are lacking, and it is not approved by the FDA or EMA.
Key Information
Classification
Key Takeaways
- Semax is a synthetic ACTH(4-10)-analog heptapeptide studied mainly in Russian research
- Animal studies describe neuroprotective and nootropic-associated effects; it is reported in Russian clinical use
- It is not approved by the FDA or EMA, and independent large trials are limited
Scientific Overview
In Plain English
Semax is a lab-made peptide based on a fragment of the hormone ACTH. Most research comes from Russian animal studies on brain protection and cognition, and it is used clinically in Russia. It is not approved as a medicine in the US or Europe, and large independent trials are limited.
Scientific Details
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analog of the ACTH(4-10) fragment lacking corticotropic activity. Preclinical studies, largely from Russian groups, describe activation of neurotrophin transcription after cerebral ischemia, effects on immune- and vascular-related gene expression in ischemia models, and activation of dopaminergic and serotonergic systems in rodents. It is reported in Russian clinical use; independent large-scale controlled trials are limited.
How It Works
Semax is described in research as an ACTH(4-10) analog associated with neuroprotective and nootropic effects, including reported activation of neurotrophin (BDNF-related) gene expression and modulation of brain monoamine systems, in animal models of ischemia and cognition. These mechanisms are characterized preclinically and are not confirmed by large controlled international trials.
Mechanism of Action
Neurotrophin gene activation
animal
Animal ischemia studies associate Semax with increased transcription of neurotrophins and their receptor genes.
Monoaminergic modulation
animal
Rodent studies report activation of dopaminergic and serotonergic systems, consistent with reported nootropic effects.
Evidence Level
Human Evidence
Semax is reported in Russian clinical practice for stroke and cognitive indications; independent, large-scale controlled international trials are limited, and it is not approved by the FDA or EMA.
Animal Evidence
Rodent studies describe neuroprotective and gene-expression effects in cerebral-ischemia models.
Cell Evidence
Studies describe effects on gene expression relevant to neurotrophic and vascular signaling.
Limitations
The literature is concentrated in Russian research groups and predominantly preclinical; independent replication and large controlled human trials are limited.
Why This Grade
Graded low: beyond preclinical animal work there is reported Russian clinical use, but limited independent, large-scale controlled human evidence and no FDA/EMA approval.
References
- Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology.Animal Studydoi:10.1007/s10571-009-9432-0 →
- The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics.Animal Studydoi:10.1186/1471-2164-15-228 →
Alternative Names
- ACTH(4-10) analog
- Met-Glu-His-Phe-Pro-Gly-Pro
Risks & Safety
- Not approved by the FDA or EMA; safety and efficacy are not established by those standards
- Independent human safety data are limited
- Research-chemical-vendor material is not quality-controlled and may be mislabeled or contaminated
- Long-term effects are not well characterized outside a limited body of research
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals or investigational drugs not approved for general human use. Consult a licensed healthcare provider. This entry does not assert that Semax is safe or effective for any use and is not a recommendation to obtain or use it.
This page summarizes published research and is for informational purposes only; it is not medical advice.